Defendant Name: Zymergen Inc.

Defendant Type: Subsidiary of Public Company

Document Reference: 34-106074

Document Details

Legal Case Name In the Matter of Zymergen Inc.
Document Name Order Appointing Tax Administrator
Document Date 11-Aug-2026
Document Format Administrative Proceeding
File Number 3-22112
Allegation Type Issuer Reporting and Disclosure
Document Summary The Commission ordered that: "Heffler, Radetich & Saitta, LLP is appointed as the Tax Administrator for the QSF in the above-referenced proceeding."

Disgorgement & Penalty Information

Resolutions
The Commission ordered that: "Heffler, Radetich & Saitta, LLP is appointed as the Tax Administrator for the QSF in the above-referenced proceeding."

Related Documents:

33-11303 13-Sep-2024 Administrative Proceeding
Order Instituting Cease-And-Desist Proceedings Pursuant to Section 8A of the Securities Act of 1933, Making Findings, And Imposing a Cease-And-Desist Order
On September 13, 2024, the SEC instituted cease-and-desist proceedings against Zymergen Inc., stating: "These proceedings arise from Zymergen's misrepresentations and omissions during and after its initial public offering ("IPO") in April 2021. Zymergen was a biotechnology company focused on the manufacture of novel materials, including optical films used in electronic screens. From at least March to August 2021, Zymergen misled investors about its lone developed product's market opportunity, revenue prospects, and customer pipeline."
2024-129 13-Sep-2024 Press Release--Administrative Proceeding
SEC Charges Zymergen Inc. With Misleading IPO Investors About Company's Market Potential and Sales Prospects
On September 13, 2024, the SEC "today announced settled charges against Zymergen Inc., an Emeryville, California-based biotechnology company, for misleading IPO investors about its overall market potential, revenue prospects, and customer pipeline for its only commercially available product, an electronics film named Hyaline. Zymergen raised approximately $530 million through its IPO in April 2021 and fi led for bankruptcy in 2023. Zymergen agreed to pay a $30 million civil penalty to resolve the SEC's charges."